| Title |
Advances in antiplatelet technologies to improve cardiovascular disease morbidity and mortality: a review of ticagrelor
|
|---|---|
| Published in |
Clinical Pharmacology : Advances and Applications, April 2013
|
| DOI | 10.2147/cpaa.s41859 |
| Pubmed ID | |
| Authors |
Estella M Davis, Jon T Knezevich, Robyn M Teply |
| Abstract |
Antiplatelet therapy is widely used with proven benefit for the prevention of further ischemic cardiac complications in patients with acute coronary syndrome. Treatment guidelines for acute coronary syndrome and percutaneous coronary intervention now recommend the use of oral antiplatelet agents including ticagrelor, prasugrel, or clopidogrel in combination with aspirin to comprise dual antiplatelet therapy for the prevention of recurrent ischemic events. The limitations of conventional antiplatelet therapy with clopidogrel or prasugrel include the potential for low response to clopidogrel identified through platelet reactivity or genetic testing, increased risk of bleeding with prasugrel, or slower return to normal platelet activity in patients who received either prasugrel or clopidogrel prior to emergent or planned surgical procedures. This review will discuss the pharmacokinetic and pharmacodynamic properties of ticagrelor in comparison to conventional P2Y12 receptor inhibitors and its utility in patients identified as low responders to clopidogrel. Completed clinical studies and substudies comparing ticagrelor to clopidogrel and ongoing clinical trials evaluating ticagrelor in acute coronary syndrome patients will also be reviewed. |
X Demographics
The data shown below were collected from the profiles of 3 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Switzerland | 1 | 33% |
| Unknown | 2 | 67% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 3 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 41 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 41 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Master | 6 | 15% |
| Researcher | 5 | 12% |
| Student > Postgraduate | 4 | 10% |
| Student > Bachelor | 4 | 10% |
| Student > Ph. D. Student | 3 | 7% |
| Other | 8 | 20% |
| Unknown | 11 | 27% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 18 | 44% |
| Biochemistry, Genetics and Molecular Biology | 3 | 7% |
| Pharmacology, Toxicology and Pharmaceutical Science | 3 | 7% |
| Mathematics | 1 | 2% |
| Computer Science | 1 | 2% |
| Other | 3 | 7% |
| Unknown | 12 | 29% |
Attention Score in Context
This research output has an Altmetric Attention Score of 5. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 02 October 2023.
All research outputs
#7,104,371
of 25,540,105 outputs
Outputs from Clinical Pharmacology : Advances and Applications
#69
of 179 outputs
Outputs of similar age
#57,147
of 213,392 outputs
Outputs of similar age from Clinical Pharmacology : Advances and Applications
#3
of 6 outputs
Altmetric has tracked 25,540,105 research outputs across all sources so far. This one has received more attention than most of these and is in the 71st percentile.
So far Altmetric has tracked 179 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 6.9. This one has gotten more attention than average, scoring higher than 59% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 213,392 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 72% of its contemporaries.
We're also able to compare this research output to 6 others from the same source and published within six weeks on either side of this one. This one has scored higher than 3 of them.